Journal of Cancer Research and Clinical Oncology最新文献

{"title":"TTK promotes HER2 + breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the Akt/mTOR axis.","authors":"Shaolin Zhang, Hua Ding, Yongfen Deng, Yu Ren, Fulin Zhou, Qian Zhang, Shu Liu","doi":"10.1007/s00432-024-06021-9","DOIUrl":"10.1007/s00432-024-06021-9","url":null,"abstract":"<p><strong>Background: </strong>HER2 + breast cancer is a malignant neoplasm with a high degree of aggressiveness and therapeutic challenge. In recent years, studies have indicated a strong correlation between TTK and various tumors, though its role in HER2 + BRCA remains unclear.</p><p><strong>Objectives: </strong>Studying the biological function of the TTK gene in HER2 + BRCA and its resistance to targeted therapy it provides new ideas for targeted drug research.</p><p><strong>Methods: </strong>TTK was knocked down by small interfering RNA transfection, and its biological function in HER2 + BRCA cells was verified, and its mechanism of action was verified by RT-PCR and Western blot.</p><p><strong>Results: </strong>The study demonstrated that TTK promoted cell proliferation and migration by activating the Akt/mTOR pathway in HER2 + breast cancer and enhanced the drug sensitivity of BRCA cell lines SKBR3 and BT474 to pyrotinib, in addition, knockdown of TTK induced apoptosis and arrested cells in G1 phase.</p><p><strong>Conclusion: </strong>Which implies that TTK is an oncogene in HER2 + BRCA and is a valuable research target.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"512"},"PeriodicalIF":2.7,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"USP33 is an integrin α6 deubiquitinase and promotes esophageal squamous cell carcinoma cell migration and metastasis.","authors":"Qinglei Hang, Shiying Zuo, Yawen Yang, Yuanzhi Wang, Caimin Li, Wenqian Li, Jingya Guo, Sicong Hou, Haifeng Huang","doi":"10.1007/s00432-024-06041-5","DOIUrl":"10.1007/s00432-024-06041-5","url":null,"abstract":"<p><strong>Purpose: </strong>The deubiquitinating enzymes (DUBs) have been linked to cancer initiation and progression. Although ubiquitin-specific protease 33 (USP33) represents a significant factor in regulating various tumor cell behaviors, its specific biological functions and precise mechanisms in esophageal squamous cell carcinoma (ESCC) progression remain unclear.</p><p><strong>Methods: </strong>The expressions of USP33 mRNA in GEO databases, clinical ESCC samples, and USP33 protein were analyzed using bioinformatics, RT-PCR, and immunohistochemistry, respectively. Using Kaplan-Meier survival curves, the log-rank test was used to determine the cumulative survival rate. Western blotting was used to determine indicated protein expression. The cell biological functions were evaluated by cell growth assay, transwell, cell adhesion, and cell spreading assay, respectively. The interaction between USP33 and integrins was detected by immunoprecipitation, and the deubiquitination was performed by deubiquitination assay. The metastatic ability was checked by tail vein injection.</p><p><strong>Results: </strong>A significant positive correlation was found between USP33 expression and clinical TNM stage, T classification, and poor prognosis in patients with ESCC. USP33 promoted laminin-dependent adhesion, spreading, and migration of ESCC cells but not their proliferation. Mechanistically, USP33 mediates cell migration through binding, deubiquinating, and stabilizing integrin α6. USP33 knockdown could inhibit ESCC cell migration and metastasis majorly through integrin α6.</p><p><strong>Conclusion: </strong>This study reveals a novel mechanism of USP33 in promoting laminin-dependent ESCC cell migration and metastasis through integrin α6, suggesting that USP33 may be a promising target for treating ESCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"511"},"PeriodicalIF":2.7,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric evaluation of different cylinder diameters in three-dimensional vaginal brachytherapy for early-stage endometrial cancer.","authors":"Kaiyue Wang, Ping Jiang, Junjie Wang","doi":"10.1007/s00432-024-05994-x","DOIUrl":"10.1007/s00432-024-05994-x","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the dosimetric, radiobiological, and toxicity differences between different cylinder diameters (d) in high-dose-rate three-dimensional computed-tomography-guided vaginal brachytherapy (VBT) for early-stage endometrial cancer (EC).</p><p><strong>Methods: </strong>From January 2019 to January 2024, postoperative EC patients treated with exclusive VBT using cylinders were classified by the cylinder diameter (d ≤ 2.6 cm: small-size; d ≥ 3.0 cm: large-size) and matched according to 1:2 propensity score matching. Vaginal clinical target volume (CTV) was a 3-mm expansion around the cylinder surface. Dosimetric parameters in equivalent dose in 2 Gy (EQD2) (α/β = 3 Gy) and equivalent uniform dose (EUD) of vaginal_CTV and organs at risk (OARs) were evaluated. Urinary, gastrointestinal, and vaginal toxicities were assessed using CTCAE v5.0.</p><p><strong>Results: </strong>After matching, 132 patients (small-size: 44; large-size: 88) were analyzed. For vaginal_CTV, the small-size group had higher doses to 2%, 5%, 0.1 cc, 1 cc, and 2 cc of the volume (D₂, D₅, D_0.1 cc, D_1cc, and D_2cc) than the large-size group while lower doses to the 95%, 98%, and 100% volume (D₉₅, D₉₈, and D₁₀₀). The D_2cc and D_5cc of bladder and all dosimetric parameters of rectum were smaller in the small-size group. The EUD of vaginal_CTV, bladder, and rectum showed no significant differences. No significant differences in toxicities were found within the median follow-up of 26.8 months.</p><p><strong>Conclusion: </strong>Cylinders with smaller diameters produced more nonuniform dose distributions in the target and delivered lower doses to bladder and rectum than large-size cylinders. However, the dosimetric differences did not translate into significant differences of radiobiological parameters or outcomes.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"510"},"PeriodicalIF":2.7,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of the SOX2 gene in cervical cancer: focus on ferroptosis and construction of a predictive model.","authors":"Shenping Liu, Zhi Wei, Huiqing Ding","doi":"10.1007/s00432-024-05973-2","DOIUrl":"10.1007/s00432-024-05973-2","url":null,"abstract":"<p><strong>Background: </strong>The intricate interplay between stemness markers and cell death pathways significantly influences the pathophysiology of cervical cancer. SOX2, a pivotal regulator of stem cell pluripotency, has recently been implicated in the modulation of ferroptosis, a specialized form of iron-dependent cell death, in cancer dynamics. This study delineates the role of SOX2 in the ferroptotic landscape of cervical carcinoma.</p><p><strong>Objective: </strong>To delineate the association between SOX2 expression and ferroptosis in cervical cancer and develop a robust, SOX2-centric model for predicting prognosis and enhancing personalized treatment.</p><p><strong>Methods: </strong>A multidimensional approach integrating advanced bioinformatics, comprehensive molecular profiling, and state-of-the-art machine learning algorithms was employed to assess SOX2 expression patterns and their correlation with ferroptosis marker expression patterns in cervical cancer tissues. A prognostic model incorporating the expression levels of SOX2 and ferroptosis indicators was meticulously constructed.</p><p><strong>Results: </strong>This investigation revealed a profound and intricate correlation between SOX2 expression and ferroptotic processes in cervical cancer, substantiated by robust molecular evidence. The developed predictive model based on SOX2 expression exhibited superior prognostic accuracy and may guide therapeutic decision-making.</p><p><strong>Conclusion: </strong>This study underscores the critical role of SOX2 in orchestrating the ferroptosis pathway in cervical cancer and presents a novel prognostic framework. The SOX2-centric predictive model represents a significant advancement in prognosis evaluation, offering a gateway to personalized treatment for gynaecologic cancers.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"509"},"PeriodicalIF":2.7,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11585523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteopontin: an indispensable component in common liver, pancreatic, and biliary related disease.","authors":"Lu Liu, Kunwei Niu, Zhipeng Yang, Junbo Song, Dan Wei, Ruohan Zhang, Kaishan Tao","doi":"10.1007/s00432-024-06038-0","DOIUrl":"10.1007/s00432-024-06038-0","url":null,"abstract":"<p><strong>Background: </strong>The liver, gallbladder, and pancreas constitute a critically important system of digestive and endocrine organs in the human body, performing essential and complex physiological functions. At present, diseases of this digestive system have a high incidence in the world and is a more common disease. However, osteopontin (OPN) plays a crucial role in common liver, pancreatic, and biliary diseases, and its mechanisms of action merit further exploration and study.</p><p><strong>Methods: </strong>We performed an analysis to assess the role of osteopontin in liver, pancreatic, and biliary diseases, focusing on its significance in these conditions.</p><p><strong>Results: </strong>Osteopontin, a profoundly phosphorylated glycoprotein, can be utilized as a diagnostic marker for hepatocellular carcinoma and cholangiopathies. Additionally it assists in the treatment of non-alcoholic fatty liver disease and promotes the proliferation, migration, and invasion of pancreatic cancer cells. Furthermore, osteopontin regulates inflammatory responses in chronic pancreatitis.</p><p><strong>Conclusions: </strong>This review offers a thorough analysis of the genetic and protein architecture of OPN, and elucidates the relationship between osteopontin and liver, pancreatic, and biliary diseases. Furthermore, exclusive focus is lavished on the potential utility of OPN as a biomarker and an innovative therapeutic target in the management of these disorder.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"508"},"PeriodicalIF":2.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11582231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of sintilimab combined with neoadjuvant chemotherapy and trastuzumab in conversional treatment of locally advanced HER2-positive gastric cancer: case analysis and literature review.","authors":"Sidikjan Ibrahim, Amina Maimaitiaili, Guangsheng Zhu, Shengwei Ye","doi":"10.1007/s00432-024-06024-6","DOIUrl":"10.1007/s00432-024-06024-6","url":null,"abstract":"<p><strong>Background: </strong>Regional lymph nodes that are fixed and fused into clusters or those exhibiting metastases outside the regional lymph nodes are generally classified as stage IV (M1) or unresectable. Patients with such nodes almost always need pre-operative treatment so that they can undergo surgical resection. Combining immunotherapy with trastuzumab and chemotherapy significantly improved the prognosis of HER-2 positive gastric/gastroesophageal junction (G/GEJ) cancer. However, very few reports are available on the role of immunotherapy in converting patients with unresectable cancer to resectable cancer.</p><p><strong>Methods: </strong>In this study, we report on four patients with GC who were preoperatively treated with a combination of sintilimab, trastuzumab, and chemotherapy at Hubei Cancer Hospital, China, from January 2022 to October 2023. Both preoperative and postoperative clinical and pathological characteristics of each patient were analyzed. The preoperative tumor stage was cT4N3M1.</p><p><strong>Results: </strong>Postoperative pathological results showed that two patients achieved pathological complete remission (pCR), while the pathological stage in the other two patients decreased to ypT1N0M0 and ypT2N0M0. None of them had nerve or vascular invasion. None of the patients had recurrences or metastases until the last follow-up (October 2024) after primary surgery. The present case report suggests that a combination of immunotherapy comprising trastuzumab and chemotherapy can improve the efficiency of conversion therapy for patients with HER-2 positive locally advanced G/GEJ cancer. This study also demonstrates the safety of immune checkpoint inhibitors in a conversional treatment approach.</p><p><strong>Conclusion: </strong>We showed that a pathological complete response (pCR) can be obtained even with unresectable advanced GC through treatment with sintilimab combined with neoadjuvant chemotherapy and trastuzumab.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"507"},"PeriodicalIF":2.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a novel molecular classification for hepatocellular carcinoma based on disulfideptosis-related genes and its potential prognostic significance.","authors":"Tao Wang, Yong Liu, Junjie Kong, Jun Liu","doi":"10.1007/s00432-024-06031-7","DOIUrl":"10.1007/s00432-024-06031-7","url":null,"abstract":"<p><strong>Background: </strong>Globally, hepatocellular carcinoma (HCC) is one of the most prevalent and deadly malignant tumors. A recent study proposed disulfidptosis, a novel form of regulated cell death (RCD), offering a new avenue for identifying tumor prognosis biomarkers and developing novel therapeutic targets.</p><p><strong>Methods: </strong>Based on the expression data of 14 disulfideptosis-related genes extracted from public databases, a new molecular classification of HCC called the \"disulfidptosis score\" was constructed and its relationship to tumor immunity and prognosis was evaluated.</p><p><strong>Results: </strong>Based on the expression of disulfideptosis-related genes, we performed cluster analysis on HCC samples from the TCGA cohort, which classified these patients into three clusters: A, B, and C, and the differentially expressed genes of different clusters were analyzed. A disulfidptosis score model was constructed by differentially expressed genes associated with prognosis. Univariate and multivariate COX regression analysis showed that disulfidptosis score was an independent prognostic factor for HCC. In addition, in various disulfidptosis score groups, notable disparities were observed concerning the tumor immune microenvironment as well as the expression of immune checkpoint.</p><p><strong>Conclusion: </strong>Disulfidptosis score have an important role in predicting HCC prognosis and help guide us in providing better immunotherapy options for patients.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"506"},"PeriodicalIF":2.7,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-classification of breast cancer pathology images based on a two-stage hybrid network.","authors":"Guolan Wang, Mengjiu Jia, Qichao Zhou, Songrui Xu, Yadong Zhao, Qiaorong Wang, Zhi Tian, Ruyi Shi, Keke Wang, Ting Yan, Guohui Chen, Bin Wang","doi":"10.1007/s00432-024-06002-y","DOIUrl":"10.1007/s00432-024-06002-y","url":null,"abstract":"<p><strong>Background and objective: </strong>In current clinical medicine, pathological image diagnosis is the gold standard for cancer diagnosis. After pathologists determine whether breast lesions are malignant or benign, further sub-type classification is often necessary.</p><p><strong>Methods: </strong>For this task, this study designed a multi-classification model for breast cancer pathological images based on a two-stage hybrid network. Due to limited sample size for breast sub-type data, this study selected the ResNet34 network as the base network and improved it as the first-level convolutional network, using transfer learning to assist network training. In order to compensate for the lack of long-distance dependencies in the convolutional network, the second-level network was designed to use Long Short-Term Memory (LSTM) to capture contextual information in the images for predictive classification.</p><p><strong>Results: </strong>For the 8 sub-types of breast cancer classification on the BreakHis (40×, 100×, 200×, 400×) dataset, the ensemble model achieved accuracy rates of 93.67%, 97.08%, 98.01%, and 94.73% respectively. For the 4 sub-types of breast cancer classification on the ICIAR2018 (200×) dataset, the ensemble model achieved accuracy, precision, recall, and F1 Score rates of 93.75%, 92.5%, 92.5%, and 92.5% respectively.</p><p><strong>Conclusion: </strong>The results show that the multi-classification model proposed in this study outperforms other methods in terms of classification performance, and further demonstrate that the proposed RFSAM module is beneficial for improving model performance.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"505"},"PeriodicalIF":2.7,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Multiparametric MRI based deep learning model for prediction of early recurrence of hepatocellular carcinoma after SR following TACE.","authors":"Hongyu Wang, Jinwei Li, Yushu Ouyang, He Ren, Chao An, Wendao Liu","doi":"10.1007/s00432-024-06027-3","DOIUrl":"10.1007/s00432-024-06027-3","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 11","pages":"504"},"PeriodicalIF":2.7,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age differences in the treatment of lung cancer-a cohort study among 42,000 patients from Germany.","authors":"Nikolaj Rischke, Josephine Kanbach, Ulrike Haug","doi":"10.1007/s00432-024-06025-5","DOIUrl":"10.1007/s00432-024-06025-5","url":null,"abstract":"<p><strong>Aims: </strong>We aimed to describe treatment of lung cancer patients in Germany based on health claims data, focusing particularly on differences by age.</p><p><strong>Materials and methods: </strong>Using the German Pharmacoepidemiological Research Database (GePaRD, ~ 20% of the German population) we identified lung cancer patients diagnosed in 2015-2018 based on a previously developed algorithm and followed them until death, end of continuous insurance or end of 2020. We described initial treatment patterns after diagnosis and survival, stratified among others by age.</p><p><strong>Results: </strong>We included 42,629 incident lung cancer patients (58% male). Surgery within three months after diagnosis was performed in 36%, 31%, 29% and 18% of patients aged < 50, 50-69, 70-79 and ≥ 80, respectively. Among patients without surgery, systemic therapy was administered in 77%, 72%, 54% and 25% of patients aged < 50, 50-69, 70-79 and ≥ 80, respectively. Monoclonal antibodies were administered in 15-30% of patients across age groups, and 4% to 15% received protein kinase inhibitors. Overall, 21% of patients remained untreated. In the age groups < 50, 50-69, 70-79 and ≥ 80, this proportions was 9%, 12%, 22% and 48%, respectively.</p><p><strong>Conclusion: </strong>In conclusion, our study provides a comprehensive overview of the therapy of lung cancer patients in Germany and quantitatively demonstrates the considerable differences between age groups. In terms of clinical cancer registration, the results are useful to estimate the completeness of data for the different types of treatment.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 11","pages":"503"},"PeriodicalIF":2.7,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11568014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}